American Journal of Biomedical Science & Research Publishes GATC Health Research Article, “Learning to Discover: The Impact of AI in Preclinical Drug Development”

IRVINE, Calif., November 20, 2024 — GATC Health Corp, a technology company revolutionizing disease prediction and drug discovery using artificial intelligence (AI), announces that The American Journal of Biomedical Science & Research has published a paper entitled “Learning to Discover: The Impact of AI in Preclinical Drug Development,” co-authored by GATC's Samuel Kho, Waldemar Lernhardt, Eric J Mathur, Jayson Uffens, Ian Jenkins, and Jonathan RT Lakey.

The paper discusses the transformative role of AI in addressing the productivity challenges in pharmaceutical drug development, highlighting GATC Health’s innovative AI-powered pipeline for enhancing preclinical drug discovery processes.

Key points from the publication include:

• Integration of deep learning models that better understand context and relationships help overcomethe limitations of reductionist strategies for drug discovery. 

• GATC Health's comprehensive AI-powered pipeline, which enhances various stages of preclinical drug discovery, from assay development to lead optimization.

• The potential of AI to accelerate timelines, reduce costs, and improve the precision and efficiency of drug development.

This research underscores GATC Health's commitment to creating cutting-edge AI technologies that revolutionize the drug discovery process and address the long-standing productivity issues in pharmaceutical development.

GATC Health will continue to publish scientific insights as part of our mission to transform drug discovery and improve human health. We welcome inquiries and dialogue about this vital work.

About GATC Health

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach.  The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.